| Top down characterization of larger proteins (45 kDa) by electron capture dissociation mass spectrometry Y Ge, BG Lawhorn, M ElNaggar, E Strauss, JH Park, TP Begley, ... Journal of the American Chemical Society 124 (4), 672-678, 2002 | 472 | 2002 |
| Biosynthesis of the thiamin pyrimidine: the reconstitution of a remarkable rearrangement reaction BG Lawhorn, RA Mehl, TP Begley Organic & biomolecular chemistry 2 (17), 2538-2546, 2004 | 94 | 2004 |
| Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart RJ Vagnozzi, GJ Gatto Jr, LS Kallander, NE Hoffman, K Mallilankaraman, ... Science translational medicine 5 (207), 207ra141-207ra141, 2013 | 73 | 2013 |
| Total synthesis and evaluation of cytostatin, its C10− C11 diastereomers, and additional key analogues: impact on PP2A inhibition BG Lawhorn, SB Boga, SE Wolkenberg, DA Colby, CM Gauss, ... Journal of the American Chemical Society 128 (51), 16720-16732, 2006 | 70 | 2006 |
| A genetic screen for the identification of thiamin metabolic genes BG Lawhorn, SY Gerdes, TP Begley Journal of Biological chemistry 279 (42), 43555-43559, 2004 | 64 | 2004 |
| Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and (β12–β13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight … MR Swingle, L Amable, BG Lawhorn, SB Buck, CP Burke, P Ratti, ... Journal of Pharmacology and Experimental Therapeutics 331 (1), 45-53, 2009 | 62 | 2009 |
| Identification of purines and 7-deazapurines as potent and selective type I inhibitors of troponin I-interacting kinase (TNNI3K) BG Lawhorn, J Philp, Y Zhao, C Louer, M Hammond, M Cheung, H Fries, ... Journal of medicinal chemistry 58 (18), 7431-7448, 2015 | 45 | 2015 |
| Recent advances in TRPV4 agonists and antagonists BG Lawhorn, EJ Brnardic, DJ Behm Bioorganic & Medicinal Chemistry Letters 30 (8), 127022, 2020 | 44 | 2020 |
| Detection of four oxidation sites in viral prolyl‐4‐hydroxylase by top‐down mass spectrometry Y Ge, BG Lawhorn, M ElNaggar, SK Sze, TP Begley, FW McLafferty Protein Science 12 (10), 2320-2326, 2003 | 44 | 2003 |
| Discovery of GSK2798745: a clinical candidate for inhibition of transient receptor potential vanilloid 4 (TRPV4) CA Brooks, LS Barton, DJ Behm, HS Eidam, RM Fox, M Hammond, ... ACS medicinal chemistry letters 10 (8), 1228-1233, 2019 | 39 | 2019 |
| Design and optimization of sulfone pyrrolidine sulfonamide antagonists of transient receptor potential vanilloid-4 with in vivo activity in a pulmonary edema model JE Pero, JM Matthews, DJ Behm, EJ Brnardic, C Brooks, BW Budzik, ... Journal of Medicinal Chemistry 61 (24), 11209-11220, 2018 | 27 | 2018 |
| TRPV4 antagonists: A patent review (2015–2020) BG Lawhorn, EJ Brnardic, DJ Behm Expert Opinion on Therapeutic Patents 31 (9), 773-784, 2021 | 25 | 2021 |
| Substituent effects on drug–receptor H-bond interactions: correlations useful for the design of kinase inhibitors BG Lawhorn, J Philp, AP Graves, DA Holt, GJ Gatto Jr, LS Kallander Journal of Medicinal Chemistry 59 (23), 10629-10641, 2016 | 25 | 2016 |
| Discovery of pyrrolidine sulfonamides as selective and orally bioavailable antagonists of transient receptor potential vanilloid-4 (TRPV4) EJ Brnardic, G Ye, C Brooks, C Donatelli, L Barton, J McAtee, ... Journal of Medicinal Chemistry 61 (21), 9738-9755, 2018 | 23 | 2018 |
| 4, 6-Diaminopyrimidines as highly preferred troponin I-interacting kinase (TNNI3K) inhibitors J Philp, BG Lawhorn, AP Graves, L Shewchuk, KL Rivera, LJ Jolivette, ... Journal of medicinal chemistry 61 (7), 3076-3088, 2018 | 23 | 2018 |
| Reverse hydroxamate inhibitors of bone morphogenetic protein 1 LS Kallander, D Washburn, MA Hilfiker, HS Eidam, BG Lawhorn, ... ACS Medicinal Chemistry Letters 9 (7), 736-740, 2018 | 21 | 2018 |
| Discovery of GSK3527497: A candidate for the inhibition of transient receptor potential vanilloid-4 (TRPV4) CA Brooks, LS Barton, DJ Behm, EJ Brnardic, MH Costell, DA Holt, ... Journal of Medicinal Chemistry 62 (20), 9270-9280, 2019 | 20 | 2019 |
| GSK114: A selective inhibitor for elucidating the biological role of TNNI3K BG Lawhorn, J Philp, AP Graves, L Shewchuk, DA Holt, GJ Gatto Jr, ... Bioorganic & Medicinal Chemistry Letters 26 (14), 3355-3358, 2016 | 13 | 2016 |
| Renin Inhibitors JJ Baldwin, S Cacatian, D Claremon, LW Dillard, PT Flaherty, ... US Patent App. 12/665,217, 2010 | 9 | 2010 |
| Total synthesis of cytostatin BG Lawhorn, SB Boga, SE Wolkenberg Heterocycles: an international journal for reviews and communications in …, 2006 | 9 | 2006 |
